On January 15, 2020, HistoSonics’ research on non-thermal histotripsy tumor ablation was published in the Journal for ImmunoTherapy of Cancer (JITC), the premier cancer immunotherapy journal at BMC and the official journal of the Society for Immunotherapy of Cancer (SITC). …
Latest News From Lumira Ventures
HistoSonics Leads The Observer’s 2020 List of Innovative Healthcare Companies
PLYMOUTH, Minn. /PRNewswire/ — HistoSonics, developer of a novel non-invasive sonic beam therapy platform, was named by The Observer as one of the nation’s most influential healthcare companies during the 38th J.P. Morgan Healthcare Investment Conference in San Francisco, CA. The …
HistoSonics Receives 2019 Frost & Sullivan Technology Innovation Award
SAN ANTONIO /PRNewswire/ — Frost & Sullivan, a leading global research and analysis firm, announced that it has awarded HistoSonics its prestigious 2019 North American Technology Innovation Award for the development of the company’s new breakthrough platform, designed to destroy solid …
HistoSonics Touts First-in-Human Study Results
HistoSonics announced its non-invasive robotics platform and novel sonic beam cancer therapy successfully destroyed 11 tumors in eight patients during its first clinical trial. The results were presented this week at the 2019 Society of Interventional Oncology (SIO) Annual Meeting …
HistoSonics, Non-Invasive Robotics Pioneer, Closes $54 Million Series C Financing
Breakthrough medical platform offers vision of personalized tumor treatments with its novel sonic beam therapy ANN ARBOR, MICHIGAN // Apr. 8, 2019 – HistoSonics, developer of a non-invasive robotics platform and novel beam therapy, announced today that it has closed …